Text size :

Drugs, Murzilli (Aaiito): “Biologics are a Copernican revolution in severe asthma”

ADNKRONOS

November 10, 2026

Rome, Nov 10. (Adnkronos Health) – “Biological drugs, on the market for a few years, have certainly represented a Copernican revolution in the management of patients with severe asthma. Their mechanism of action is targeted and precise on the inflammation of allergic asthma, blocking the inflammatory process at certain points and leading to a clinical improvement in the patient. This allows for a reduction in relapses, emergency room visits, and hospitalizations, drastically improving the patient’s quality of life and reducing the direct and indirect costs associated with this type of pathology.” This was stated by Francesco Murzilli, president of Aaiito – Association of Italian Territorial and Hospital Allergists and Immunologists and Director of Allergology at S. Filippo e Nicola Hospital in Avezzano (L’Aquila), today in Rome, at the Senate Library during the meeting ‘Respiratory Health in Italy and Therapeutic Innovation. Towards a shared roadmap for severe asthma, COPD and nasal polyposis’.”

“Before, we simply relied on the use of systemic corticosteroid drugs, with all the side effects associated with this type of therapy, such as osteoporosis, diabetes, hypertension, and gastroesophageal reflux, which could worsen the patient’s quality of life and the control of severe asthma – explains the expert – Currently, there are about 6 biological drugs on the market, which act at different levels, but depemokimab, a new biological drug characterized by being administered every six months, is about to be launched. Registration studies have documented how this drug, while maintaining high levels of efficacy and safety standards, allows the patient to have better adherence to therapy. Administering a drug once every six months, in fact, improves the patient’s quality of life and adherence to therapy. However, about 20% of patients with severe asthma do not respond even to these drugs, probably because the mechanisms underlying inflammation are heterogeneous and the biological drugs currently available cannot interact with all of them or block them – Murzilli continues – In this context, therapeutic innovation is moving towards the search for molecules that can act at multiple levels, perhaps intervening on combined and coexisting inflammatory pathways. For example, work is underway on the synthesis of products that can act at a higher level in inflammation, of type T2 or even non-T2, in order to intercept the inflammatory processes that lead to the disease further upstream. Drugs are being synthesized that can lead to a greater blockage of IgE production, which is the cause of inflammation in these subjects.”

“There are also pre-existing conditions that need to be controlled – emphasizes the expert – For example, there are asthmatic patients who still smoke, or patients suffering from certain comorbidities, such as nasal polyposis and thus chronic rhinosinusitis, or gastroesophageal reflux. All these conditions can stimulate the reactivation of asthmatic disease and an increase in relapses, with consequent emergency room visits and hospitalizations. In this context, it is very important to educate patients and doctors and ensure that, once identified as actually suffering from severe bronchial asthma, the patient is appropriately treated with the currently available medical devices,” he concludes.”

Jiji Press

Related

Page TOP